---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-020536"
form_type: "8-K"
ticker: "RVPH"
cik: "0001742927"
company_name: "REVIVA PHARMACEUTICALS HOLDINGS, INC."
filed_at: "2023-07-24T23:59:59+00:00"
generated_at: "2026-06-13T04:20:44.766965+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Reviva Pharmaceuticals' auditor Armanino declines re-appointment; audit committee seeks new firm

## Summary
- Armanino LLP notified Reviva on July 18, 2023 it will not stand for re-appointment after Q3 2023 review.
- Reason: Armanino is transitioning away from providing audit services to public companies.
- Audit reports for FY2021 and FY2022 were unqualified; FY2022 included a going-concern paragraph.
- No disagreements or reportable events occurred during the period through July 18, 2023.
- Audit committee has begun search for a new independent registered public accountant for FY2023 audit.

## SEC filing metadata
- accession: 0001437749-23-020536
- form_type: 8-K
- ticker: RVPH
- cik: 0001742927
- company_name: REVIVA PHARMACEUTICALS HOLDINGS, INC.
- filed_at: 2023-07-24T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 4.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1742927/000143774923020536/0001437749-23-020536-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1742927/000143774923020536/rvph20230721_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-020536
- JSON: https://secwatch.observer/filing/0001437749-23-020536.json
- Plain text: https://secwatch.observer/filing/0001437749-23-020536.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.